{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:54:52Z","timestamp":1761897292499,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014805","name":"Roche Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clml.2020.05.006","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T21:48:04Z","timestamp":1589320084000},"page":"e629-e644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed\/Refractory Multiple Myeloma Treated With Lenalidomide"],"prefix":"10.1016","volume":"20","author":[{"given":"Barbara","family":"Gamberi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Berthou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpietro","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Tholouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Caers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjorn","family":"Andreasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Parreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Crotty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Remes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Kueenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rosettani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Di Micco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.05.006_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hon.2205","article-title":"Improved survival of older patients with multiple myeloma in the era of novel agents","volume":"34","author":"Mey","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2020.05.006_bib2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.05.006_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.24236","article-title":"Myeloma today: disease definitions and treatment advances","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.05.006_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bjh.14780","article-title":"Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions","volume":"179","author":"Moreau","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.05.006_bib5","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1038\/bcj.2016.15","article-title":"Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma","volume":"6","author":"Binder","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.05.006_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2020.05.006_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2020.05.006_bib8","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1038\/bcj.2012.47","article-title":"Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules","volume":"3","author":"Leich","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.05.006_bib9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.006_bib10","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.05.006_bib11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2020.05.006_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"Holstein","year":"2018","journal-title":"Ther Adv Hematol"},{"year":"2019","series-title":"Revlimid (lenalidomide). [Package insert]","key":"10.1016\/j.clml.2020.05.006_bib13"},{"key":"10.1016\/j.clml.2020.05.006_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.clml.2020.05.006_bib15","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.05.006_bib16","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate ikaros and aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.05.006_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.clml.2020.05.006_bib18","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.006_bib19","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.006_bib20","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A\u00a0randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.006_bib21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12185-012-1125-7","article-title":"Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients \u2265 65 years old with relapsed or refractory multiple myeloma","volume":"96","author":"Chanan-Khan","year":"2012","journal-title":"Int J Hematol"},{"year":"2019","series-title":"Revlimid (lenalidomide). [Summary of product characteristics]. European Medicines Agency","key":"10.1016\/j.clml.2020.05.006_bib22"},{"key":"10.1016\/j.clml.2020.05.006_bib23","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.05.006_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"year":"2019","series-title":"Velcade (bortezomib). [Summary of product characteristics]. European Medicines Agency","key":"10.1016\/j.clml.2020.05.006_bib25"},{"year":"2019","series-title":"Velcade (bortezomib) for injection, for subcutaneous or intravenous use, ed. [Package insert]","key":"10.1016\/j.clml.2020.05.006_bib26"},{"key":"10.1016\/j.clml.2020.05.006_bib27","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A\u00a0review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.006_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.05.006_bib29","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood.V122.21.5397.5397","article-title":"Lenalidomide related diarrhea correlates with survival in multiple myeloma [Abstract]","volume":"122","author":"Faiman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.006_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.leukres.2018.03.008","article-title":"Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials","volume":"68","author":"Knauf","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.05.006_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:47Z","timestamp":1761870887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020302342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2152265020302342"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed\/Refractory Multiple Myeloma Treated With Lenalidomide","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}